BladderChek Test
This article was originally published in The Tan Sheet
Executive Summary
Diagnostic products developers Matritech and Inverness Medical Innovations have signed a manufacturing and distribution agreement to collaborate and seek FDA approval for OTC sale of the NMP22 BladderChek Test, the companies announce Nov. 6. The product, developed by Matritech, is the only FDA approved physician-office test for both the diagnosis and monitoring of bladder cancer, the companies say. The firms will assess market opportunity under their agreement and "anticipate the OTC distribution would be introduced in the U.S. as soon as FDA approval is received." Home diagnostic products already marketed by Inverness include the Clearblue and Fact Plus home pregnancy tests...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.